Results 221 to 230 of about 45,745 (258)
Some of the next articles are maybe not open access.
Therapeutic monoclonal antibodies
The Lancet, 2000The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. Chimeric humanised and fully humanised mAb can now be made by recombinant engineering. About a quarter of all biotech drugs in development are mAb, and around 30 products are in use or being ...
openaire +2 more sources
Antibody and antibody derivatives as cancer therapeutics
WIREs Nanomedicine and Nanobiotechnology, 2019Antibodies are an important class of therapeutic for treating a wide range of diseases. These versatile macromolecules can be engineered to target many different antigens and to utilize several mechanisms of action to produce a pharmacological effect. The most common antibody platform used for therapeutics is immunoglobulin G (IgG). Advances in protein‐
Keith J, Arlotta, Shawn C, Owen
openaire +2 more sources
Molecular Immunology, 2015
This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e.
openaire +2 more sources
This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e.
openaire +2 more sources
The Expanding Role of Therapeutic Antibodies
International Reviews of Immunology, 2014Therapeutic antibodies have been used since the end of nineteenth century, but their use is progressively increased and recently, with the availability of monoclonal antibodies, they are successfully employed in a large disease spectrum, which transversally covers different fields of medicine.
Simonetta Salemi +3 more
openaire +3 more sources
Antibody engineering for therapeutics
Current Opinion in Structural Biology, 2003With the acceptance of antibodies as therapeutics, a diversity of engineered antibody forms have been created to improve their efficacy, including enhancing the effector functions of full-length antibodies, delivering toxins to kill cells or cytokines in order to stimulate the immune system, and bispecific antibodies to target multiple receptors. After
openaire +2 more sources
Recombinant therapeutic antibodies
Applied Microbiology and Biotechnology, 2007Recombinant antibody technology has revolutionized the development of antibody therapeutics. This minireview offers an overview of enabling technologies and future prospects of this rapidly progressing field.
openaire +2 more sources
Therapeutic Antibodies for Biodefense
2017Diseases can be caused naturally by biological agents such as bacteria, viruses and toxins (natural risk). However, such biological agents can be intentionally disseminated in the environment by a State (military context) or terrorists to cause diseases in a population or livestock, to destabilize a nation by creating a climate of terror, destabilizing
openaire +2 more sources
Expert Opinion on Biological Therapy, 2007
Recombinant monoclonal antibody (rMAb) therapy may be instituted to achieve one of two broad outcomes: i) killing of cells or organisms (e.g., cancer cells, bacteria); and ii) neutralisation of soluble molecules (e.g., cytokines in chronic disease or toxins in infection).
openaire +2 more sources
Recombinant monoclonal antibody (rMAb) therapy may be instituted to achieve one of two broad outcomes: i) killing of cells or organisms (e.g., cancer cells, bacteria); and ii) neutralisation of soluble molecules (e.g., cytokines in chronic disease or toxins in infection).
openaire +2 more sources
Therapeutic antibody expression technology
Current Opinion in Biotechnology, 2001With the technological advances made during the past decade, antibodies now represent an important and growing class of biotherapeutics. With the potential new targets resulting from genomics and with methods now in place to make fully human antibodies, the potential of antibodies as valuable therapeutics in oncology, inflammation and cardiovascular ...
H E, Chadd, S M, Chamow
openaire +2 more sources
2023
LGR5 binding agents, in particular antibodies or fragments thereof which bind to human LGR5, and the use of such binding agents in the treatment of disease, such as cancer and inflammatory disease, and the detection of LGR5.
De La Roche, Maike +3 more
openaire +1 more source
LGR5 binding agents, in particular antibodies or fragments thereof which bind to human LGR5, and the use of such binding agents in the treatment of disease, such as cancer and inflammatory disease, and the detection of LGR5.
De La Roche, Maike +3 more
openaire +1 more source